Major Histocompatibility Complex class II presenting New York esophageal squamous cell carcinoma 1-derived peptides (MHC II/NY-ESO-1 complex)

The MHC class II molecules presenting NY-ESO-1-derived peptides constitute a critical target in cancer immunotherapy, specifically for the activation of CD4+ T helper cells. NY-ESO-1 (encoded by the CTAG1B gene) is a well-characterized cancer-testis antigen that is highly expressed in various tumors, such as synovial sarcoma and melanoma, but restricted in normal tissues to the immune-privileged testes (UniProt P78358). When NY-ESO-1 is processed by antigen-presenting cells, its peptides are loaded onto MHC class II molecules (e.g., HLA-DP4, HLA-DR) and displayed on the cell surface (PubMed 11160736). Recognition of these peptide-MHC complexes by specific T-cell receptors (TCRs) triggers the activation of CD4+ T cells, which are essential for sustaining long-term anti-tumor immunity and enhancing the recruitment of cytotoxic CD8+ T cells (PubMed 15155838). Therapeutic approaches targeting this complex include TCR-engineered T-cell therapies and multi-epitope vaccines designed to overcome the limitations of MHC class I-restricted treatments (PubMed 24755471). By engaging the helper arm of the immune system, these therapies aim to provide a more durable and comprehensive response against NY-ESO-1-positive malignancies.

Other names

HLA class II/NY-ESO-1 complexpMHC II (NY-ESO-1)HLA-DP4/NY-ESO-1 complexHLA-DR/NY-ESO-1 complexCTAG1B/MHC II complexHLA-DPB1*04:01/NY-ESO-1 complex

Recognition of specific NY-ESO-1 peptide epitopes (such as NY-ESO-1 157-170) presented within the binding groove of MHC Class II molecules by the T-cell receptor (TCR) of CD4+ T cells, leading to T-cell activation, secretion of pro-inflammatory cytokines (e.g., IFN-gamma), and orchestration of a broader anti-tumor immune response.